Heather Roberts
Orthopaedic Surgery · San Francisco, CANPI 1427411487
Payments from drug & device makers
Across 16 payments — averaging $91.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$452
- Stryker$306
- Davol Inc.$198
- Encore Medical, LP$187
- Innovation Technologies Inc$125
- Pacira Pharmaceuticals Incorporated$117
- plus $80 from 1 others
What the payments were for
- Food & beverage$1,465100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $452 |
| Stryker | 4 | $306 |
| Davol Inc. | 2 | $198 |
| Encore Medical, LP | 3 | $187 |
| Innovation Technologies Inc | 1 | $125 |
| Pacira Pharmaceuticals Incorporated | 1 | $117 |
| Exactech, Inc. | 1 | $80 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ATTUNE$289
- GMRS$157
- ARISTA AH FLEXITIP$132
- Irrisept$125
- Iovera$117
How this compares
$1,465 in reported general payments places this provider in the 40th percentile of 1,808 orthopaedic surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 13 | $2,457 |
| Celecoxib | 113 | $1,474 |
| Cephalexin | 146 | $590 |
| Oxycodone Hcl | 103 | $446 |
| Ondansetron OdtOndansetron | 48 | $225 |
| Mupirocin | 26 | $221 |
| Diclofenac Sodium | 14 | $195 |
| Pantoprazole Sodium | 14 | $82 |
| Hydromorphone Hcl | 14 | $68 |
| Clindamycin Hcl | 23 | $66 |
| Dexamethasone | 19 | $65 |
| Tramadol Hcl | 13 | $23 |
Paid to pharmacies, not to this prescriber.
Other orthopaedic surgery in San Francisco
- Tom NorrisSan Francisco$5.3M
- Sigurd BervenSan Francisco$4.1M
- Vedat DevirenSan Francisco$2.9M
- James KellySan Francisco$1M
- Eugene WolfSan Francisco$988K
- Alexander TheologisSan Francisco$719K
- Bradford HackArcadia$18.3M
- Robert GorabOrange$14.5M
- Kelly VinceLos Angeles$9.6M
- Stephen HowellSacramento$9.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.